Back to search

Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Data up to Jan 2025

Published2002
Citations531
References26

Total Citations Per Year

Abstract

References (26)

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1988 • 19,632 citations

Revised Criteria for the Classification of Rheumatoid Arthritis

1990 • 7,730 citations

Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1995 • 5,929 citations

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

2000 • 2,992 citations

American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

1995 • 2,778 citations

Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis

2001 • 2,229 citations

<scp>gp</scp>130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES

1997 • 1,468 citations

Etanercept Therapy in Rheumatoid Arthritis

1999 • 1,407 citations

The Pathophysiologic Roles of Interleukin-6 in Human Disease

1998 • 1,132 citations

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

1998 • 956 citations

Interleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1988 • 859 citations

Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis

1988 • 793 citations

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

1996 • 538 citations

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

1989 • 514 citations

Textbook of Rheumatology

1994 • 434 citations

TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?

1992 • 377 citations

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

1994 • 299 citations

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

1993 • 278 citations

A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

2000 • 210 citations

lnterleukin-6 (IL-6) in Synovial Fluid and Serum of Patients with Rheumatic Diseases

1988 • 143 citations

Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis.

1992 • 133 citations

Long-Term Outcomes in Rheumatoid Arthritis

1995 • 114 citations

Interleukin-6 and its receptor in autoimmunity

1992 • 82 citations

Management of rheumatoid arthritis

1997 • 26 citations

Antirheumatic gold compounds and penicillamine enhance protein kinase C-mediated activation of the arachidonate- mobilizing phospholipase A2 in mouse macrophages

1993 • 13 citations

IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs

1992 • 6 citations

Cited By (0)

Loading...
Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6… (2002) – Arthritis & Rheumatism | Metascience Observatory Explorer